End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.74 USD | -0.69% | -0.82% | +109.04% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Business Summary
Number of employees: 53
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Medicines
100.0
%
| 0 | nan % | 3 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 3 | 100.0 % | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 29,349,469 | 26,756,178 ( 91.16 %) | 0 | 91.16 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+109.04% | 638M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- DNTH Stock
- Company Dianthus Therapeutics, Inc.